Share on StockTwits

Shares of Protalix BioTherapeutics (NYSE:PLX) were the target of a significant decline in short interest in June. As of June 30th, there was short interest totalling 5,770,699 shares, a decline of 1.0% from the June 13th total of 5,828,771 shares, Analyst Ratings News reports. Approximately 8.0% of the company’s shares are sold short. Based on an average trading volume of 190,246 shares, the short-interest ratio is presently 30.3 days.

A number of analysts have recently weighed in on PLX shares. Analysts at JPMorgan Chase & Co. cut their price target on shares of Protalix BioTherapeutics from $8.00 to $7.00 in a research note on Tuesday, May 13th. They now have an “overweight” rating on the stock. Analysts at Jefferies Group reiterated a “hold” rating on shares of Protalix BioTherapeutics in a research note on Monday, May 12th. They now have a $4.25 price target on the stock, down previously from $5.50.

Shares of Protalix BioTherapeutics (NYSE:PLX) opened at 3.25 on Monday. Protalix BioTherapeutics has a one year low of $3.16 and a one year high of $5.72. The stock’s 50-day moving average is $3.74 and its 200-day moving average is $4.27. The company’s market cap is $301.2 million.

Protalix BioTherapeutics (NYSE:PLX) last issued its quarterly earnings data on Thursday, May 22nd. The company reported ($0.08) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.07) by $0.01. Analysts expect that Protalix BioTherapeutics will post $-0.22 EPS for the current fiscal year.

Protalix BioTherapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.